Jonea Lim, MD
Endocrinology, Diabetes & Metabolism · Oklahoma City, OKNPI 1285774331
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $428 of the $654 with a category attached, or 65.4%. 6 manufacturers reported payments, led by Novo Nordisk at 34.6% of the total. 2023 is the largest year on record at $389, 2.8 times the $141 reported in 2019. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in OK, where the typical reported total is $2,620.
Across 13 payments — averaging $50.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$226
- Medtronic$142
- Sanofi-aventis U.S. LLC$123
- Pfizer$76
- Lilly USA, LLC$66
- Abbott$22
Across 327 payments — averaging $529.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$94K
- Corcept Therapeutics$54K
- Sanofi US Services Inc.$25K
What the payments were for
- Food & beverage$42865%
- Education$22635%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 7 | $226 |
| Medtronic | 1 | $142 |
| Sanofi-aventis U.S. LLC | 1 | $123 |
| Pfizer | 1 | $76 |
| Lilly USA, LLC | 2 | $66 |
| Abbott | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$142
- SOLIQUA 100/33$123
How this compares
$654 in reported general payments places this provider in the 20th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
See all endocrinology, diabetes & metabolism providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 72 | $140,142 |
| MounjaroTirzepatide | 74 | $126,811 |
| JardianceEmpagliflozin | 52 | $72,725 |
| GenotropinSomatropin | 19 | $34,076 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $31,188 |
| TrulicityDulaglutide | 14 | $29,194 |
| Tresiba Flextouch U-100Insulin Degludec | 41 | $27,730 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 21 | $21,900 |
| JanuviaSitagliptin Phosphate | 27 | $18,936 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 87 | $16,531 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 21 | $8,755 |
| Humalog Kwikpen U-100Insulin Lispro | 17 | $7,085 |
| SynthroidLevothyroxine Sodium | 48 | $3,450 |
| Hydrocortisone | 55 | $3,394 |
| Levothyroxine Sodium | 289 | $3,380 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $66 | $156,00488 claims |
| Novo NordiskOzempic | $226 | $140,14272 claims |
| PfizerGenotropin | $76 | $34,07619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
Other endocrinology, diabetes & metabolism in Oklahoma City
- Christian MangrumOklahoma City$54K
- Robert ScofieldOklahoma City$15K
- Donny WynnOklahoma City$11K
- Cheryl BlackOklahoma City$8K
- Diana KennedyOklahoma City$8K
- Ali TipuOklahoma City$8K
- Amanda LagrecaOklahoma City$7K
- Bassam ArodakOklahoma City$6K
- Myrto EliadesOklahoma City$5K
- Hamsa AljumailiOklahoma City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.